Glucotrack, Inc. (GCTK) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Glucotrack reported revenue of $0. Net income was -$19.4M, or $468.30 per diluted share. Operating activities generated -$15.2M of cash, leaving -$15.3M of free cash flow. At fiscal year end, Glucotrack held $7.8M in total assets against $5.0M in total liabilities, including $7.4M of cash and equivalents.
Open the full interactive Glucotrack financials → Quarterly statements, key ratios, valuation history and price charts.
Glucotrack Key Stats
| Share Price | $1.11 |
|---|---|
| Market Cap | $370,672 |
| P/E Ratio | 0.0 |
| 52-Week Range | $1.03 – $115.35 |
| Shares Outstanding | 333,939 (basic, 2026 Q2) |
Glucotrack Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 |
| Operating Income | $3.1M | -$4.0M | -$4.4M | -$7.1M | -$14.5M | -$16.1M |
| Pre-Tax Income | -$2.7M | -$4.1M | -$4.4M | -$7.1M | -$22.6M | -$19.4M |
| Income Tax | -$5.4M | — | — | — | — | — |
| Net Income | $2.7M | -$4.1M | -$4.4M | -$7.1M | -$22.6M | -$19.4M |
| Diluted EPS | -$23400.00 | $23400.00 | — | $34200.00 | $61596.00 | $468.30 |
Glucotrack Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.2M | -$3.6M | -$4.3M | -$3.8M |
| Diluted EPS | $69.60 | -$5.84 | $39.75 | $11.40 |
Glucotrack Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.8M | $6.1M | $2.3M | $4.5M | $5.6M | $7.4M |
| Current Assets | $10.2M | $6.1M | $2.4M | $4.9M | $5.8M | $7.7M |
| Total Assets | $10.6M | $6.3M | $2.4M | $4.9M | $5.9M | $7.8M |
| Current Liabilities | $1.3M | $883,000 | $1.0M | $1.5M | $1.3M | $4.8M |
| Total Liabilities | $1.6M | $1.1M | $1.2M | $1.7M | $18.9M | $5.0M |
| Shareholders' Equity | $9.0M | $5.2M | $1.2M | $3.2M | -$13.0M | $2.8M |
Glucotrack Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.5M | -$3.8M | -$3.7M | -$6.6M | -$12.5M | -$15.2M |
| Cash From Investing | -$53,000 | -$1,000 | $1,000 | — | -$104,000 | -$96,000 |
| Cash From Financing | $13.0M | — | — | $8.7M | $13.7M | $17.0M |
| Free Cash Flow | -$3.6M | -$3.8M | -$3.7M | -$6.6M | -$12.6M | -$15.3M |
Figures from Glucotrack's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Glucotrack financials page for every line item.
Glucotrack Company Profile
| Ticker | GCTK |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Rutherford, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001506983 |
Frequently Asked Questions
What was Glucotrack's revenue in fiscal 2025?
Glucotrack (GCTK) reported revenue of $0 for fiscal 2025.
What is Glucotrack's annual revenue history?
Glucotrack's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Glucotrack's net income in fiscal 2025?
Glucotrack reported net income of -$19.4M for fiscal 2025.
What was Glucotrack's earnings per share (EPS) in fiscal 2025?
Glucotrack's diluted EPS was $468.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Glucotrack generate in fiscal 2025?
Glucotrack generated -$15.3M of free cash flow in fiscal 2025.
What was Glucotrack's revenue last quarter?
In its most recent reported quarter (2026 Q2), Glucotrack reported revenue of $0.
How many shares of Glucotrack are outstanding?
Glucotrack reported a weighted average of 333,939 basic shares outstanding in 2026 Q2.
What is Glucotrack's market cap?
Based on its latest closing price, Glucotrack (GCTK) has a market capitalization of about $370,672.
When does Glucotrack's fiscal year end?
Glucotrack's fiscal year end, as registered with the SEC, is December 31.
Where is Glucotrack headquartered?
Glucotrack lists its business address in Rutherford, New Jersey in its SEC filings.
Glucotrack Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →